Regenerx Biopharmaceuticals Inc (RGRX) 0.3990 $RGRX
RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Aug 30, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU
PR Newswire - Mon Aug 29, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company's proprietary molecule Thymosin beta 4 (TB4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.
RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
PR Newswire - Wed Aug 24, 7:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree, LLC, has received permission from the U.S. FDA to proceed with a second Phase 3 clinical trial using RGN-259 to treat patients with dry eye syndrome (DES).
RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company's Product Candidates
PR Newswire - Wed Aug 03, 12:10PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient. The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (TB4) over a period of time, as well as treating a patient by maintaining a desired concentration of TB4 in a pharmacologically effective range. The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.
Thymosin Beta 4 Effective in Treatment of Heart Attack Patients
PR Newswire - Tue Jun 14, 11:54AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a publication of a pilot clinical trial demonstrating that Thymosin beta 4 (TB4) was effective in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI), or heart attack
RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
PR Newswire - Wed Jun 01, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. ("RegeneRx", OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Ltd., ("Lee's Pharm", HKEx Stock Code: 0950), a fully integrated bio-pharmaceutical company headquartered in Hong Kong, today announced acceleration of development of RGN-259 in China. According to Lee's Pharm, the Company's licensee and partner in China, in April the Chinese Food and Drug Administration (CFDA) modified its regulations for conducting clinical trials in China with "locally" developed drug candidates that have been partially developed outside of the country, as is the case with RGN-259.
RegeneRx Comments on Valuation
PR Newswire - Fri May 27, 10:47AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, made the following comments today on its stock price:
RegeneRx Releases Letter to Stockholders
PR Newswire - Tue May 17, 7:59AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today released the following letter to stockholders regarding its recent Phase 2/3 dry eye clinical trial:
Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating
PR Newswire - Tue May 10, 10:21AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of H.C. Wainwright & Co., has updated its analyst report on RegeneRx Biopharmaceuticals, Inc. The firm has reiterated a Buy rating with a 12-month price target of $2 per share. The report is authored by Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D., CFA. All recommendations and targets are based on the analysis of Rodman & Renshaw.
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye
PR Newswire - Fri May 06, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced positive results from its second clinical trial evaluating RGN-259 for the treatment of dry eye sponsored by ReGenTree LLC, its U.S. joint venture with GtreeBNT in Korea. The 317-patient Phase 2/3 trial (ClinicalTrials.gov Identifier: NCT02597803) demonstrated statistically significant improvements in both signs and symptoms of dry eye with 0.05% and 0.1% RGN-259 compared to placebo in a dose dependent manner during a 28-day dosing period. While the primary outcome measures were not met, several key related pre-specified endpoints and subgroups of patients with more severe dry eye showed statistically significant treatment effects. These results confirm the findings from the previous Phase 2 trial providing clear direction for the clinical regulatory pathway and remaining registration trials for RGN-259.
RegeneRx and ReGenTree Expand License for Dry Eye
PR Newswire - Thu Apr 28, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" today announced that it has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the U.S. to the U.S. and Canada. The license expansion was negotiated pursuant to a term sheet that was previously announced by RegeneRx in its most recent Form 10-K. RegeneRx previously received a payment from ReGenTree of $250,000 under the term sheet, which is the license fee for the expanded territory. The U.S. license between the two companies has been amended to include Canada, and the Canadian territory will be subject to the same royalty structure as currently exists.
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.19), OMER: 10.74 (-0.33), ATHX: 1.91 (-0.03), KPTI: 9.95 (+0.22), CUR: 0.28 (-0.02)
RegeneRx to Receive EU Patent for Use of TB4 in Preventing And Treating Damage Associated with Reperfusion Injury
PR Newswire - Wed Apr 06, 10:12AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent Office (EPO) has notified the Company that it intends to grant a patent covering the "Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow." The patent will cover protection, treatment, inhibition or reduction of damaged of tissue due to the increase of blood flow such as can occur when opening a blocked artery in the heart, also known as reperfusion injury, or in the central nervous system, as in the case of the treatment of certain types of stroke. The patent will also cover TB4 fragments and analogues and may be used with or without other agents, devices or procedures during treatment. The patent expires in 2027.
Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 34.80 (-0.08)
RegeneRx concludes patient enrollment in Phase 2b/3 US dry eye trial of RGN-259
M2 - Mon Feb 01, 3:56AM CST
Drug company RegeneRx Biopharmaceuticals (Other OTC:RGRX) stated on Friday that it has completed enrolment of its Phase 2b/3 dry eye trial of RGN-259 in the US.
RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells
PR Newswire - Wed Jan 27, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the publication of a new scientific study demonstrating how Thymosin beta 4 (TB4) initiates remyelination (restoration of the myelination sheath around nerve cells responsible for fast and accurate transmission of nerve signals) by promoting the differentiation of oligodendrocyte progenitor cells (OPCs) in two separate demyelination animal models, including the experimental autoimmune encephalomyelitis (EAE) model and the cuprizone diet model, both commonly used for studying different aspects of MS-related pathology.
Keratitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffh6vw/keratitis) has announced the addition of the "Keratitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Keratitis Overview - Therapeutics Development - Pipeline Products for Keratitis - Overview - Pipeline Products for Keratitis - Comparative Analysis - Keratitis - Therapeutics under Development by Companies - Keratitis - Therapeutics under Investigation by Universities/Institutes - Keratitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Keratitis - Products under Development by Companies - Keratitis - Products under Investigation by Universities/Institutes - Keratitis - Companies Involved in Therapeutics Development - Adamis Pharmaceuticals Corporation - Cellceutix Corporation - NanoViricides, Inc. - Peregrine Pharmaceuticals, Inc. - ReceptoPharm, Inc. - RegeneRx Biopharmaceuticals, Inc. - Sirnaomics, Inc. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/ffh6vw/keratitis
ADMP: 2.95 (+0.07), NNVC: 1.51 (-0.03)
RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov
PR Newswire - Wed Dec 23, 9:08AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its joint venture with G-treeBNT, ReGenTree LLC, has posted final results from the first placebo-controlled, double-masked, exploratory Phase 2 clinical trial using RGN-259 eye drops in patients with severe dry eye on www.clinicaltrials.gov (search "thymosin and severe dry eye" , which were previously published earlier this year in the medical journal, Cornea; May 2015;34:491-496.
RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment
PR Newswire - Fri Dec 04, 8:39AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx" , a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Chinese State Intellectual Property Office (SIPO) has issued a patent for a key peptide fragment of Thymosin beta 4 (TB4) to RegeneRx. The patent claims are directed to both composition of matter and methods of use, including suppressing inflammation, stimulating cell migration, protecting tissue from cytotoxicity, inhibiting apoptosis, inhibiting tissue damage caused by UV radiation, and stimulating elastin, among others. The patent expiry is expected to be in 2029.
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.51 (-1.29), RIGL: 3.37 (-0.56), OCUL: 6.39 (-0.38), AGN: 234.54 (-2.45), SHPG: 187.18 (-3.04), MRK: 62.79 (+0.08), CLTX: 36.01 (+16.34)
RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PR Newswire - Tue Aug 30, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City. RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU
PR Newswire - Mon Aug 29, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company's proprietary molecule Thymosin beta 4 (TB4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026. RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
PR Newswire - Wed Aug 24, 7:00AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree, LLC, has received permission from the U.S. FDA to proceed with a second Phase 3 clinical trial using RGN-259 to treat patients with dry eye syndrome (DES). RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company's Product Candidates
PR Newswire - Wed Aug 03, 12:10PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient. The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (TB4) over a period of time, as well as treating a patient by maintaining a desired concentration of TB4 in a pharmacologically effective range. The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO. Thymosin Beta 4 Effective in Treatment of Heart Attack Patients
PR Newswire - Tue Jun 14, 11:54AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a publication of a pilot clinical trial demonstrating that Thymosin beta 4 (TB4) was effective in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI), or heart attack RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
PR Newswire - Wed Jun 01, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. ("RegeneRx", OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Ltd., ("Lee's Pharm", HKEx Stock Code: 0950), a fully integrated bio-pharmaceutical company headquartered in Hong Kong, today announced acceleration of development of RGN-259 in China. According to Lee's Pharm, the Company's licensee and partner in China, in April the Chinese Food and Drug Administration (CFDA) modified its regulations for conducting clinical trials in China with "locally" developed drug candidates that have been partially developed outside of the country, as is the case with RGN-259.
RegeneRx Comments on Valuation
PR Newswire - Fri May 27, 10:47AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, made the following comments today on its stock price:
RegeneRx Releases Letter to Stockholders
PR Newswire - Tue May 17, 7:59AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today released the following letter to stockholders regarding its recent Phase 2/3 dry eye clinical trial:
Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating
PR Newswire - Tue May 10, 10:21AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of H.C. Wainwright & Co., has updated its analyst report on RegeneRx Biopharmaceuticals, Inc. The firm has reiterated a Buy rating with a 12-month price target of $2 per share. The report is authored by Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D., CFA. All recommendations and targets are based on the analysis of Rodman & Renshaw.
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye
PR Newswire - Fri May 06, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced positive results from its second clinical trial evaluating RGN-259 for the treatment of dry eye sponsored by ReGenTree LLC, its U.S. joint venture with GtreeBNT in Korea. The 317-patient Phase 2/3 trial (ClinicalTrials.gov Identifier: NCT02597803) demonstrated statistically significant improvements in both signs and symptoms of dry eye with 0.05% and 0.1% RGN-259 compared to placebo in a dose dependent manner during a 28-day dosing period. While the primary outcome measures were not met, several key related pre-specified endpoints and subgroups of patients with more severe dry eye showed statistically significant treatment effects. These results confirm the findings from the previous Phase 2 trial providing clear direction for the clinical regulatory pathway and remaining registration trials for RGN-259. RegeneRx and ReGenTree Expand License for Dry Eye
PR Newswire - Thu Apr 28, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
today announced that it has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the U.S. to the U.S. and Canada. The license expansion was negotiated pursuant to a term sheet that was previously announced by RegeneRx in its most recent Form 10-K. RegeneRx previously received a payment from ReGenTree of $250,000 under the term sheet, which is the license fee for the expanded territory. The U.S. license between the two companies has been amended to include Canada, and the Canadian territory will be subject to the same royalty structure as currently exists. Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.19), OMER: 10.74 (-0.33), ATHX: 1.91 (-0.03), KPTI: 9.95 (+0.22), CUR: 0.28 (-0.02)
RegeneRx to Receive EU Patent for Use of TB4 in Preventing And Treating Damage Associated with Reperfusion Injury
PR Newswire - Wed Apr 06, 10:12AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent Office (EPO) has notified the Company that it intends to grant a patent covering the "Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow." The patent will cover protection, treatment, inhibition or reduction of damaged of tissue due to the increase of blood flow such as can occur when opening a blocked artery in the heart, also known as reperfusion injury, or in the central nervous system, as in the case of the treatment of certain types of stroke. The patent will also cover TB4 fragments and analogues and may be used with or without other agents, devices or procedures during treatment. The patent expires in 2027. Peripheral Neuropathy (Sensory) Market Pipeline Global Review H2 2015
PR Newswire - Mon Mar 28, 1:00PM CDT
New market research titled "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" provides an overview of the Peripheral Neuropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
PFE: 34.80 (-0.08)
RegeneRx concludes patient enrollment in Phase 2b/3 US dry eye trial of RGN-259
M2 - Mon Feb 01, 3:56AM CST
Drug company RegeneRx Biopharmaceuticals (Other OTC:RGRX) stated on Friday that it has completed enrolment of its Phase 2b/3 dry eye trial of RGN-259 in the US.
RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells
PR Newswire - Wed Jan 27, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the publication of a new scientific study demonstrating how Thymosin beta 4 (TB4) initiates remyelination (restoration of the myelination sheath around nerve cells responsible for fast and accurate transmission of nerve signals) by promoting the differentiation of oligodendrocyte progenitor cells (OPCs) in two separate demyelination animal models, including the experimental autoimmune encephalomyelitis (EAE) model and the cuprizone diet model, both commonly used for studying different aspects of MS-related pathology. Keratitis Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ffh6vw/keratitis) has announced the addition of the "Keratitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Keratitis Overview - Therapeutics Development - Pipeline Products for Keratitis - Overview - Pipeline Products for Keratitis - Comparative Analysis - Keratitis - Therapeutics under Development by Companies - Keratitis - Therapeutics under Investigation by Universities/Institutes - Keratitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Keratitis - Products under Development by Companies - Keratitis - Products under Investigation by Universities/Institutes - Keratitis - Companies Involved in Therapeutics Development - Adamis Pharmaceuticals Corporation - Cellceutix Corporation - NanoViricides, Inc. - Peregrine Pharmaceuticals, Inc. - ReceptoPharm, Inc. - RegeneRx Biopharmaceuticals, Inc. - Sirnaomics, Inc. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/ffh6vw/keratitis
ADMP: 2.95 (+0.07), NNVC: 1.51 (-0.03)
RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov
PR Newswire - Wed Dec 23, 9:08AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its joint venture with G-treeBNT, ReGenTree LLC, has posted final results from the first placebo-controlled, double-masked, exploratory Phase 2 clinical trial using RGN-259 eye drops in patients with severe dry eye on www.clinicaltrials.gov (search "thymosin and severe dry eye" , which were previously published earlier this year in the medical journal, Cornea; May 2015;34:491-496. RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment
PR Newswire - Fri Dec 04, 8:39AM CST
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"
, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Chinese State Intellectual Property Office (SIPO) has issued a patent for a key peptide fragment of Thymosin beta 4 (TB4) to RegeneRx. The patent claims are directed to both composition of matter and methods of use, including suppressing inflammation, stimulating cell migration, protecting tissue from cytotoxicity, inhibiting apoptosis, inhibiting tissue damage caused by UV radiation, and stimulating elastin, among others. The patent expiry is expected to be in 2029. Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.51 (-1.29), RIGL: 3.37 (-0.56), OCUL: 6.39 (-0.38), AGN: 234.54 (-2.45), SHPG: 187.18 (-3.04), MRK: 62.79 (+0.08), CLTX: 36.01 (+16.34)
1
